Saul Ewing LLP is proud to announce that Charles M. Lizza, Vice Chair of the firm’s Litigation Department, was named to the 2025 NJBIZ Law Power list. This is the seventh year in a row that Mr. Lizza has been included on this list of the state's top lawyers. Professionals are selected for the list based on their legal acumen and the results they have achieved for their clients in the state.
Mr. Lizza currently serves as lead New Jersey litigation counsel in more than three dozen patent cases for approximately 20 major pharmaceutical companies. This year, Mr. Lizza is representing BioNTech against Moderna to protect BioNTech’s COMIRNATY COVID-19 vaccine, in a case that will likely impact patents using mRNA technology for future vaccines. Prior examples of his work include representation of Helsinn Healthcare S.A. in major trial victories against Teva and Dr. Reddy’s involving the Aloxi brand drug product (market value of judgments $3.2 billion) and representing Janssen Pharmaceuticals, Inc. (“J&J”) and Mitsubishi Tanabe Pharma Corp. in a complete trial victory against Zydus involving the compound patent covering Janssen’s blockbuster Invokana diabetes drug product, with annual sales in the billions.
In public service, Mr. Lizza serves on the Board of Trustees of Saint Peter's University.
Mr. Lizza's profile notes, “Lizza leads Saul Ewing’s patent litigation team, which is routinely recognized as one of the top firms nationally for Abbreviated New Drug Application cases on behalf of brand pharmaceutical companies. He has been named one of ‘America’s Leading Lawyers in Intellectual Property Law’ by Chambers USA since 2011 and has been ranked in its highest Band since 2018.”
